Quantifying Biogenic Bias in Screening Libraries
暂无分享,去创建一个
Jérôme Hert | Brian K. Shoichet | Michael J. Keiser | Christian Laggner | John J. Irwin | J. Irwin | B. Shoichet | C. Laggner | J. Hert | Christian Laggner
[1] A. Barabasi,et al. Drug—target network , 2007, Nature Biotechnology.
[2] Peter Ertl,et al. Quest for the rings. In silico exploration of ring universe to identify novel bioactive heteroaromatic scaffolds. , 2006, Journal of medicinal chemistry.
[3] G. Bemis,et al. The properties of known drugs. 1. Molecular frameworks. , 1996, Journal of medicinal chemistry.
[4] S. Wilhelm,et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer , 2006, Nature Reviews Drug Discovery.
[5] Ricardo Macarron,et al. Critical review of the role of HTS in drug discovery. , 2006, Drug discovery today.
[6] Sunil Gupta,et al. Comparing the chemical spaces of metabolites and available chemicals: models of metabolite-likeness , 2007, Molecular Diversity.
[7] R. Spencer,et al. High-throughput screening of historic collections: observations on file size, biological targets, and file diversity. , 1998, Biotechnology and bioengineering.
[8] A. Schuffenhauer,et al. Charting biologically relevant chemical space: a structural classification of natural products (SCONP). , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[9] Jordi Mestres,et al. Coverage and bias in chemical library design. , 2008, Current opinion in chemical biology.
[10] Peter Ertl,et al. Natural Product-likeness Score and Its Application for Prioritization of Compound Libraries , 2008, J. Chem. Inf. Model..
[11] H. L. Morgan. The Generation of a Unique Machine Description for Chemical Structures-A Technique Developed at Chemical Abstracts Service. , 1965 .
[12] Herbert Waldmann,et al. From protein domains to drug candidates-natural products as guiding principles in the design and synthesis of compound libraries. , 2002, Angewandte Chemie.
[13] D. Pereira,et al. Origin and evolution of high throughput screening , 2007, British journal of pharmacology.
[14] Y. Martin. Diverse viewpoints on computational aspects of molecular diversity. , 2001, Journal of combinatorial chemistry.
[15] Andrew C. Good,et al. Measuring CAMD Technique Performance, 2. How "Druglike" Are Drugs? Implications of Random Test Set Selection Exemplified Using Druglikeness Classification Models , 2007, J. Chem. Inf. Model..
[16] B. Roth,et al. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia , 2004, Nature Reviews Drug Discovery.
[17] Jean-Louis Reymond,et al. Virtual exploration of the small-molecule chemical universe below 160 Daltons. , 2005, Angewandte Chemie.
[18] H. Kubinyi,et al. A scoring scheme for discriminating between drugs and nondrugs. , 1998, Journal of medicinal chemistry.
[19] Herbert Waldmann,et al. Charting Biological and Chemical Space: PSSC and SCONP as Guiding Principles for the Development of Compound Collections Based on Natural Product Scaffolds , 2006 .
[20] S. Schreiber,et al. Target-oriented and diversity-oriented organic synthesis in drug discovery. , 2000, Science.
[21] G. V. Paolini,et al. Global mapping of pharmacological space , 2006, Nature Biotechnology.
[22] W. Guida,et al. The art and practice of structure‐based drug design: A molecular modeling perspective , 1996, Medicinal research reviews.
[23] Tudor I. Oprea,et al. Scaffold Topologies. 2. Analysis of Chemical Databases , 2008, J. Chem. Inf. Model..
[24] Paul A Clemons,et al. Mapping chemical space using molecular descriptors and chemical genetics: deacetylase inhibitors. , 2004, Combinatorial chemistry & high throughput screening.
[25] Hiroyuki Ogata,et al. KEGG: Kyoto Encyclopedia of Genes and Genomes , 1999, Nucleic Acids Res..
[26] S. Fox,et al. High-Throughput Screening: Searching for Higher Productivity , 2004, Journal of biomolecular screening.
[27] P. Willett,et al. Comparison of topological descriptors for similarity-based virtual screening using multiple bioactive reference structures. , 2004, Organic & biomolecular chemistry.
[28] Brian K. Shoichet,et al. ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..
[29] A. Bender,et al. Circular fingerprints: flexible molecular descriptors with applications from physical chemistry to ADME. , 2006, IDrugs : the investigational drugs journal.
[30] Stefan Wetzel,et al. Cheminformatic Analysis of Natural Products and their Chemical Space , 2007 .
[31] S. Wilhelm,et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer , 2007, Nature Reviews Drug Discovery.
[32] F. Koehn,et al. The evolving role of natural products in drug discovery , 2005, Nature Reviews Drug Discovery.
[33] Jean-Louis Reymond,et al. Virtual Exploration of the Chemical Universe up to 11 Atoms of C, N, O, F: Assembly of 26.4 Million Structures (110.9 Million Stereoisomers) and Analysis for New Ring Systems, Stereochemistry, Physicochemical Properties, Compound Classes, and Drug Discovery , 2007, J. Chem. Inf. Model..
[34] Derek S. Tan,et al. Advancing chemistry and biology through diversity-oriented synthesis of natural product-like libraries. , 2005, Current opinion in chemical biology.